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Potent antimicrobial agents have been developed as a response to the development of antibiotic-resistant bacteria,
which especially affect patients with prolonged hospitalization in Intensive Care Units (ICU) and who had been
previously treated with antimicrobials, especially third-generation cephalosporins.This study was to determine how
changes in the empirical treatment of infections in ICU patients affect the incidence of Gram-negative bacteria species
and their susceptibility to antimicrobials, and examine the impact of these changes on nosocomial infections. A
prospective interventional study was performed in a university hospital during two periods: 1) First period (September
1999 to February 2000); and 2) Second period (August 2000 to December 2000); empirical treatment was changed from
ceftriaxone and/or ceftazidime in the first period to piperacillin/tazobactam in the second. ICU epidemiological and
infection control rates, as well as bacterial isolates from upper airways were analyzed. Ceftazidime consumption
dropped from 34.83 to 0.85 DDD/1000 patients per day (p=0.004). Piperacillin/tazobactam was originally not available;
its consumption reached 157.07 DDD/1000 patients per day in the second period (p=0.0002). Eighty-seven patients and
66 patients were evaluated for upper airway colonization in the first and second periods, respectively. There was a
significant decrease in the incidence of K. pneumoniae (p=0.004) and P. mirabilis (p=0.036), restoration of K. pneumoniae
susceptibility to cephalosporins (p<0.0001) and reduction of ventilator-associated pneumonia rates (p<0.0001). However,
there was an increase in P. aeruginosa incidence (p=0.005) and increases in ceftazidime (p=0.003) and meropenem
(p<0.0001) susceptibilities. Changing antimicrobial selective pressure on multi-resistant Gram-negative bacteria
helps control ventilator-associated pneumonia and decreases antimicrobial resistance.
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Since the introduction of penicillin, bacteria have been
shown to have the capacity of developing resistance when
exposed to antibiotics. There is considerable evidence that
previous exposure to antibiotics plays an important role in
the development of resistance [1].
Nowadays, the problem of resistance is of great concern
in the hospital setting due to multi-resistant S. aureus,
Enterococcus spp., Acinetobacter spp., and Pseudomonas
spp., giving birth to the so-called post-antibiotic era [2].
There is some evidence that increased use of third-
generation cephalosporins leads to resistance in Gram-
negative bacilli, especially Citrobacter, Enterobacter, Serratia
and Providencia species, and also to emergence of extended-
spectrum beta-lactamase (ESBL)-producing bacteria [3,4].
Once this happens, the use of carbapenems, which can induce
resistance in P. aeruginosa and Acinetobacter spp. [5],
becomes mandatory.
Hospital São Paulo, a large university hospital in Brazil,
experienced an increase in ESBL-producing Klebsiella
pneumoniae in 1995, when 39% of the isolates were found to
be resistant to cephalosporins. These bacteria were not clonal;
their spread was thought to be due to the use of third-
generation cephalosporins [6]. This led to increased use of
carbapenems, favoring an increase in the incidence of
Acinetobacter baumannii [7], seen in 1998; more recently,
Pseudomonas aeruginosa became one of the most common
pathogens, mainly in the ICU setting. These latter organisms
posed a substantial therapeutic dilemma, as they also became
resistant to carbapenems, therefore making polymixin the only
therapeutic choice for them.
In an attempt to reverse the trend of increasing antibiotic
resistance, we conducted a prospective interventional study
in patients who developed any infection defined as an ICU
infection.
The main goal of our study was to determine whether or
not substitution of third-generation cephalosporins by
piperacillin/tazobactam can decrease the prevalence of
Klebsiella spp. and Enterobacter spp. resistance to
cephalosporins, so that carbapenems would be less frequently
prescribed, in order to diminish their selective pressure on P.
aeruginosa and Acinetobacter spp.
Materials and Methods
 Hospital São Paulo is a tertiary university hospital in São
Paulo, Brazil, with 624 beds, of which 40 are used for the adult
Intensive-Care Unit (ICU). Our study was conducted in a 16-
bed general ICU that provides treatment for acutely-ill
patients. All patients admitted to that ICU from September
1999 to December 2000 and who were under mechanical
ventilation for more than 48 hours were included in the study.
Patients who did not stay in the ICU for 48 hours were
excluded from the study. All patients who were in the ICU
during the study period received the proposed antibiotic for
every infection believed to be due to Gram-negative bacilli in
any site.
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The following data were recorded at admission: age, sex,
pre-existing diseases and APACHE II score. Subsequently,
the numbers of days in the ICU and mortality rates were
monitored.
Due to the need for intervention, the study had a “before-
after” design, as follows:
1. First period (from September, 1999, to February, 2000):
ceftazidime was used as the antibiotic of choice for
empirical treatment of suspected Gram-negative bacilli
infections.
2. Second period (from August 2000, to December 2000):
piperacillin/tazobactam was used for the same
indication, replacing ceftazidime.
One of the investigators made daily rounds with the ICU
team to ensure understanding and compliance to the study
protocol. Antibiotic consumption, nosocomial infection, and
microbiologic colonization were analyzed in both periods, as
described below.
Some antibiotics were selected for analysis: ceftriaxone,
ceftazidime, cefepime, imipenem, amikacin, ciprofloxacin and
piperacillin/tazobactam. Consumption of these antibiotics was
measured by using the defined daily dose (DDD), as proposed





Data on nosocomial infection and on ventilator-
associated pneumonia (VAP) were obtained according to
NNIS methodology, defined by the Centers for Disease
Control and Prevention [9]. A diagnosis of ventilator-
associated pneumonia was considered by the infectious
diseases team whenever a new or progressive
roentgenographic infiltrate developed in conjunction with
two or more of the following clinical criteria: fever,
leukocytosis and purulent tracheal aspirate.
One of us (EMJ) was responsible for collecting lower
tracheal aspirates, under sterile conditions, of all patients on
the second day of mechanical ventilation; this was repeated
every week that patients were maintained on mechanical
ventilation. The material was stored for posterior culture using
classic methods of identification; susceptibility tests were
performed by using National Committee for Clinical Laboratory
Standards (NCCLS) disc diffusion standards [10]. Discs with
ceftazidime and amoxicillin/clavulanate were used to check
for ESBL in suspected isolates.
Computer-based antibiogram records were used to
determine the prevalence of resistance to amikacin, ceftriaxone,
ceftazidime, cefepime, ciprofloxacin, imipenem and piperacillin/
tazobactam.
Statistical Analysis
The student’s t test was used to compare antibiotic
consumption and hospital-infection rates between the two
periods. Survival analysis of patient outcomes (discharge from
ICU or death) was performed by using a Cox-rank test for the
two periods. A Chi-square test was used to compare periods
in terms of prevalence of pathogens and susceptibility profile
of the isolated microorganisms. The statistical significance
level adopted was 5%. Analyses were performed using
STATISTICA for Windows 4.5™. The study was submitted




Eighty-seven and 66 patients met the criteria for analysis
in the first and second periods, respectively. There were no
significant differences in the clinical and epidemiological
characteristics of the patients between the periods (Table 1).
The survival analyses showed no significant difference in the
length of stay in ICU between the periods (p=0.19, Figure 1).
In addition, the probability of death did not differ between
periods (58.6 and 59.0%, respectively (p=0.91).
Changes in Antibiotic Use
There was no significant variation in the consumption of
most of the antibiotics (Table 2). However, there was a
significant reduction in the use of third-generation
cephalosporins and a significant increase in piperacillin/
tazobactam use.
Hospital Infection Surveillance
The nosocomial infection rate decreased from an average
of 31.75/1000 patient-days in the first period to 18.99/1,000
patient-days in the second period. This was mainly due to the
decrease in ventilator-associated pneumonia (VAP) rates,
decreasing from 19.93 VAP/1000 patient-days to 5.13 VAP/
1,000 patient-days (p < 0.0001, Figure 2).
Microbiological Surveillance
Microorganisms obtained from tracheal secretions were
analyzed. These organisms were collected from 153 patients
who met the criteria for sampling. There were decreases in the
prevalence of K. pneumoniae and P. mirabilis and an increase
in the prevalence of Pseudomonas aeruginosa (Table 3).
The rate of resistance of K. pneumoniae to ceftriaxone
and ceftazidime decreased from the first to the second period
(0.78 versus 0.07 and 0.97 versus 0.21, p<0.0001, respectively).
When these bacteria were tested for production of ESBL
enzymes, 87.9% were positive in the first period and 22.2% in
the second period (p=0.0003). Piperacillin/tazobactam was not
available in the first period, but its use in the second period
did not increase the resistance of K. pneumoniae to it (0.31 x
0.14, p=0.2).
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Table 3. Frequency of tracheal isolate results in the first and second periods
Table 1. Baseline and clinical characteristics of the cohort of patients in the intensive care unit
Characteristics First period Second period p value
(N = 87) (N = 66)
Age, years*                                                                            52.44                            54.29 0.75
Sex
Male n (%) 47 (54) 40 (60)
Female n (%) 40 (46) 26 (40) 0.41
Length of stay in intensive care (days)                             19.46                             26.06 0.08
Underlying diseases
Congestive heart failure n (%) 22 (25.28) 15 (22.73) 0.86
Chronic pulmonary disease n (%) 5 (5.74) 4 (6.06) 0.79
Malignancy n (%) 16 (18.40) 18 (27.27) 0.26
Stroke n (%) 8 (9.20) 2 (3.03) 0.21
Traumatism n (%) 8 (9.20) 9 (13.64) 0.54
Metabolic diseases n (%) 8 (9.20) 2  (3.03) 0.23
No underline diseases n (%) 15 (17.24) 13 (19.70) 0.85
Hepatic disorder 5 (5.74) 3 (4.54) 0.73
Admission diagnoses
Post-operative neurosurgery 22 (25.28) 9 (13.64) 0.11
Post-operative cardiac surgery 4 (4.60) 1 (1.51) 0.54
Post-operative pulmonary surgery 5 (5.74) 2 (3.03) 0.68
Post-operative abdominal surgery 20 (23.00) 23 (34.85) 0.15
Other surgeries 4 (4.60) 7 (10.61) 0.26
Cardiac 17 (19.54) 5 (7.57) 0.06
Respiratory 9 (10.34) 13 (19.70) 0.16
Neurological 4 (4.60) 2 3.03) 0.94
Other clinical disorders 2 (2.30) 4 (6.06) 0.44
APACHE II Score§                                                                   19.37                             17.31 0.10
* Student T test or c-square test, with Yates correction when indicated. §Values are means.
Table 2. Antibiotic consumption, in DDD
N
, in the first and second periods
Antibiotic First period Second period p*
Amikacin 35.25 7.36 0.095
Ceftriaxone 73.50 15.80 0.001
Ceftazidime 34.83 0.85 0.004
Cefepime 11.17 6.60 0.39
Ciprofloxacin 50.95 24.70 0.561
Imipenem-cilastatine 58.91 64.00 0.832
Piperacillin-tazobactam - 157.07 0.0002
* Student T test.
Microorganism First period (%) Second period (%) p*
Sterile 13 (5) 9 (4) 0.76
S. aureus 24 (9) 16 (8) 0.67
K. pneumoniae 43 (16) 14 (7) 0.004
A. baumannii 45 (17) 34 (17) 0.94
P. aeruginosa 89 (33) 94 (46) 0.005
Enterobacter spp. 13 (5) 8 (4) 0.7
Serratia spp. 10 (4) 3 (1) 0.13
P. mirabilis 13 (5) 2 (1) 0.036
Other bacteria 16 (6) 19 (9) 0.23
Candida spp. 3 (1) 5 (2) 0.16
Total 269 204
*χ-square test, with Yates correction when indicated.
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Figure 1. Survival analysis during intensive care unit stay of
patients in the two periods.
Figure 2. Rates of ventilator-associated pneumonia (VAP) in
the first and second periods, considering all cases.
* p<0.001.
There were increases in P. aeruginosa resistance to
piperacillin/tazobactam (0.60 versus 0.76, p=0.02), meropenem (0.33
versus 0.45, p<0.0001) and ciprofloxacin (0.69 versus 0.78, p<0.0001)
from the first to the second periods. Increased resistance was
also observed to ceftazidime (0.67 versus 0.86, p=0.003).
Resistance to other Gram-negative bacilli (including A.
baumannii and Enterobacter spp.) and to other antimicrobials
did not differ from the first to the second period.
Discussion
The increasing dilemma posed by the treatment of multi-
resistant Gram-negative bacteria emphasizes the importance
of interventional measures directed towards minimizing this
problem.
We tested the hypothesis that an intervention designed
to reduce the incidence of ESBL and chromosome-induced
beta-lactamase (class 1 or AmpC)-producing bacteria would
make the use of carbapenems less necessary, and therefore
would allow better control of the emergence of multi-resistant
A. baumannii and P. aeruginosa strains, which are frequently
seen in infections related to health care in ICU settings [5]. To
address this issue, we proposed a prospective-interventional
study to evaluate the impact of changing empirical antibiotic
treatment of nosocomial VAP from third-generation
cephalosporins to piperacillin/tazobactam, evaluated not only
with hospital microbiology, but also by examining clinical and
epidemiological aspects.
The intervention took place in the general ICU of Hospital
São Paulo, because antimicrobial resistance is especially
important in that unit. Recorded data on bacteremia isolates
showed a high rate of P. aeruginosa resistance to ceftazidime
(37.5%), ciprofloxacin (71.5%) and imipenem (75%).
Acinetobacter spp. was also resistant to ceftazidime in 93.2%
of isolates [11] These findings were expected because several
risk factors for antimicrobial resistance had been previously
described in ICU patients [2,12,13], including acutely and
severely-ill patients, widespread use of empirical polyvalent
antimicrobial therapy and frequent need for invasive devices
and procedures.
The demographic and epidemiological profiles of the
patients attended in the ICU did not change during the study
and the survival analysis showed no difference in the length
of stay in the ICU between the periods. In addition, there was
no difference in mortality from all causes. These findings allow
us to conclude that bias in the intended analysis was
minimized. Apparently, the study intervention caused no
measurable harm to the patients attended in that ICU.
There was good adherence to the proposed intervention,
as we found a significant decrease in ceftazidime and
ceftriaxone usage, while piperacillin/tazobactam use rapidly
increased to an average of 157.07 DDD
N
/month.
As expected, a significant reduction in K. pneumoniae
isolates resistant to ceftazidime was observed from one period
to the other, as well as a reduction in the overall incidence of
K. pneumoniae. These phenomena had been described earlier
[9-11] in reports of outbreaks of resistant K. pneumoniae
controlled by restriction of the use of third-generation
cephalosporins.
Control of chromosome-induced (class 1 or AmpC) beta-
lactamase production was also expected, since Gram-negative
bacteria develop resistance to cephalosporins when exposed
to third-generation cephalosporins. However, we were not
able to prove this. We found a significant decrease in the
incident of P. mirabilis, but no change in its susceptibility
profile, as we also found for other Gram-negative bacteria.
There is some evidence [4] that the resistance of Enterobacter
spp. is reversible by restricting the use of third-generation
cephalosporins. As our interventional period was only five
months, it may have been too short to reverse a resistance
that was not very frequent in the first period.
There was no increase in the use of carbapenems, as
opposed to the findings of Rahal et al. [13], who found a
significant increase in the use of this class of antibiotic after
the substitution of ceftazidime in their institution. Patterson
et al. [11] also evaluated the use of imipenem after the
substitution of ceftazidime with piperacillin/tazobactam,
demonstrating no difference after the changing of antibiotics.
However, the rate of use of imipenem in our ICU was very
Multi-Resistant Bacteria and VAP
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high when compared to that reported from other institutions.
In one report [15] from the ICARE surveillance project, for
instance, the rate of imipenem use was only 10 DDD per 1,000
patient-days, six times less than what we found. This may
justify the increased frequency of P. aeruginosa, along with
the increase in its resistance to imipenem. Troillet et al. [18]
analyzed the risk factors associated with the development of
imipenem-resistant P. aeruginosa and concluded that the most
important one was previous use of this antibiotic (OR 15.4;
95% CI 4.0-58.9). This is consistent with what we found in our
study, as there was an increasing incidence of imipenem-
resistant Pseudomonas strains associated with the extremely
high rate of use of this antibiotic, which might have resulted
in high selective pressure on those microorganisms. Reducing
carbapenem use was not the focus of our study. Additional
restriction in carbapenem use would probably be necessary
in order to reduce the frequency of resistant P. aeruginosa.
Even with the increased incidence of resistant P.
aeruginosa, we observed an important reduction in overall
infection rates, resulting basically from a decrease in the
ventilator-associated pneumonia rates.  Other researchers
[16,17] also suggested that antibiotic changes are effective
measures in VAP control.
In conclusion, although this was not a randomized study,
the change in empirical antibiotic treatment from third-
generation cephalosporins to piperacillin/tazobactam was
effective in reducing K. pneumoniae and P. mirabilis incidence
and in reducing ventilator-associated pneumonia rates, since
no other intervention to reduce the occurrence of this event
was used during our study. In addition, it also promoted a
significant reduction in the frequency of ceftazidime-resistant
K. pneumoniae isolates.
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